References
- Lincoff A. M., Kleiman N. S., Kottke‐Marchant K. Bivalirudin with planned or provisional abciximab versus low‐dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847–53
- Lincoff A. M., Bittl J. A., Harrington R. A. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade compared with Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. REPLACE‐2 Randomized Trial. JAMA 2003; 289: 853–63
- Robson R., White H., Aylward P., Framptom C. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose and gender. Clin Pharmacol Ther 2002; 71: 433–9
- Steinhubl S. R. Percutaneous coronary interventions in patients with renal insufficiency: A high‐risk, under‐studied cohort. Am Heart J 2003; 146: 213–4
- Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000; 12((Suppl F))33F–6
- Reddan D., Szczech L. A., O'Shea S., Califf R. M. Anticoagulation in acute cardiac care in patients with chronic kidney disease. Am Heart J 2003; 145: 586–94
- White H. The Hirulog and early Reperfusion or Occlusion (HERO)‐2 Trial Investigators. Thrombin‐specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO‐2 randomised trial. Lancet 2001; 358: 1855–63
- Chew D. P., Bhatt D. L., Kimball W. Bivalirudin provides increasing benefit with decreasing renal function: A meta‐analysis of randomized trials. Am J Cardiol 2003; 92: 919–23
- Best P. J. M., Lennon R., Gersh B. J. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146: 345–50
- Jeremias A., Bhatt D. L., Chew D. P. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002; 89: 1209–11
- Rubenstein M. H., Harrell L. C., Sheynberg B. V. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?. Circulation 2000; 102: 2966–72
- Reddan D. N., O'Shea J. C., Sarembock I. J. Treatment Effects of Eptifibatide in Planned Coronary Stent Implantation in Patients With Chronic Kidney Disease (ESPRIT Trial). Am J Cardiol 2003; 91: 17–21
- Seybert A. L. Bivalirudin administration during percutaneous coronary intervention: emphasis on high‐risk patients. Pharmacotherapy 2002; 22: 112S–8S